Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133224
Status:
TERMINATED
Last Update Posted:
2008-09-23
First Post:
2005-08-19
Brief Title:
Docetaxel in Combination With GVAX Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Sponsor:
Cell Genesys
Organization:
Cell Genesys
Study Overview
Official Title:
A Phase III Randomized Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain
Status:
TERMINATED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Accrual and treatment with CG1940CG8711 stopped due to IDMC recommendation
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy who have documented metastases with pain Patients may have had up to one prior non-taxane chemotherapy treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VITAL-2 | None | None | None |